14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:DRNA
Delisted

Dicerna Pharmaceuticals Stock Price (Quote)

$38.22
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $38.22 $38.22 Friday, 27th May 2022 DRNA stock ended at $38.22. During the day the stock fluctuated 0% from a day low at $38.22 to a day high of $38.22.
90 days $38.22 $38.22
52 weeks $19.06 $40.14

Historical Dicerna Pharmaceuticals prices

Date Open High Low Close Volume
Sep 24, 2019 $14.72 $14.92 $14.47 $14.70 479 424
Sep 23, 2019 $14.44 $14.76 $14.30 $14.64 388 334
Sep 20, 2019 $14.44 $14.68 $14.25 $14.52 467 036
Sep 19, 2019 $14.37 $14.59 $14.20 $14.43 266 352
Sep 18, 2019 $14.24 $14.45 $14.12 $14.34 302 968
Sep 17, 2019 $14.18 $14.51 $14.06 $14.32 358 934
Sep 16, 2019 $14.47 $14.70 $14.21 $14.33 348 398
Sep 13, 2019 $14.87 $14.92 $14.51 $14.61 271 745
Sep 12, 2019 $15.01 $15.16 $14.67 $14.86 265 612
Sep 11, 2019 $14.86 $15.16 $14.80 $14.97 510 737
Sep 10, 2019 $13.97 $14.87 $13.90 $14.86 320 014
Sep 09, 2019 $14.05 $14.38 $13.89 $14.06 309 214
Sep 06, 2019 $14.35 $14.45 $14.04 $14.08 301 703
Sep 05, 2019 $14.16 $14.51 $13.96 $14.36 381 345
Sep 04, 2019 $14.06 $14.21 $13.97 $14.09 323 286
Sep 03, 2019 $13.82 $14.29 $13.81 $13.99 479 394
Aug 30, 2019 $14.03 $14.14 $13.79 $13.90 272 187
Aug 29, 2019 $14.30 $14.31 $13.87 $14.01 742 488
Aug 28, 2019 $13.93 $14.45 $13.71 $14.16 446 277
Aug 27, 2019 $13.67 $14.10 $13.48 $14.00 576 086
Aug 26, 2019 $12.89 $13.66 $12.87 $13.56 407 296
Aug 23, 2019 $12.96 $13.31 $12.70 $12.77 389 350
Aug 22, 2019 $13.69 $13.73 $12.91 $13.05 583 675
Aug 21, 2019 $13.46 $13.81 $13.45 $13.56 440 964
Aug 20, 2019 $14.32 $14.47 $13.28 $13.32 530 573
Click to get the best stock tips daily for free!

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company’s development programs include DCR-PH1 for the treatment of primary hyperoxaluria type 1 (PH1) through targeting the gene encoding the liver enzyme glycolate oxidase; and other rare inherit... DRNA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT